Combined COVID-19 and flu vaccine produces immune response similar to getting the vaccines separately

Embargoed until: Publicly released: 2025-05-08 01:00

International

Photo by Mathurin NAPOLY / matnapo on Unsplash

Vaccine company Moderna's phase 3 trial of its combined influenza and COVID-19 vaccine has shown that participants had a similar immune response to both COVID-19 and the targeted influenza strains compared to a COVID-19-only Moderna vaccine and a standard flu shot. about 4000 participants aged 50+ received the multicomponent vaccine and a placebo, while another 4000 received a standard Moderna COVID-19 vaccine and a flu shot. Testing their blood after 91 days, the researchers say the multicomponent vaccine was safe and induced higher immune responses against influenza strains compared to the standard flu shot.

Media release

From: JAMA

About The Study: In this phase 3 study, mRNA-1083, an investigational, multicomponent vaccine against seasonal influenza and SARS-CoV-2, met noninferiority criteria and induced higher immune responses than recommended standard care influenza (standard and high dose) and COVID-19 vaccines against all 4 influenza strains (among those ages 50-64), the 3 clinically relevant influenza strains (among those age 65 and older), and SARS-CoV-2 (all ages), with an acceptable tolerability and safety profile.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research JAMA, Web page The URL will go live after the embargo ends

Journal/
conference: JAMA

Research:Paper

Organisation/s: Moderna Inc, USA

Funder: This study was funded by Moderna, Inc.

Media Contact/s

Contact details are only visible to registered journalists.